Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

Phase I ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Metastatic Breast ◽

Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

10.1158/1538-7445.am2015-ct330 ◽

2015 ◽

Cited By ~ 3

Author(s):

Payal D. Shah ◽

Mary E. Moynahan ◽

Shanu Modi ◽

Nicola Hamilton ◽

Betty Ann Caravella ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Phase I Study ◽

Metastatic Breast ◽

Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs14-pd5-3 ◽

2015 ◽

Cited By ~ 1

Author(s):

Payal D Shah ◽

Mary Ellen Moynahan ◽

Shanu Modi ◽

Betty Ann Caravella ◽

Farrah M Datko ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Phase I Trial ◽

Metastatic Breast ◽

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

Breast Cancer Research and Treatment ◽

10.1007/s10549-015-3615-9 ◽

2015 ◽

Vol 154 (2) ◽

pp. 287-297 ◽

Cited By ~ 14

Author(s):

Kimberly Blackwell ◽

Howard Burris ◽

Patricia Gomez ◽

N. Lynn Henry ◽

Steven Isakoff ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Aromatase Inhibitor ◽

Dose Escalation ◽

Hormone Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽

Pi3k Inhibitors ◽

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

10.1158/0008-5472.sabcs11-pd01-01 ◽

2011 ◽

Cited By ~ 6

Author(s):

GL Wright ◽

J Blum ◽

LK Krekow ◽

KJ McIntyre ◽

ST Wilks ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Randomized Phase Ii ◽

Previously Treated

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.531 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 531-531

Author(s):

Antoinette R. Tan ◽

Serena Tsan-Lai Wong ◽

Robert D. Warren ◽

Jennifer Eng-Wong ◽

Minetta C. Liu ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Hormone Receptor ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Hormone Receptor Positive ◽

Line Therapy

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

Annals of Oncology ◽

10.1016/j.annonc.2020.09.004 ◽

2020 ◽

Vol 31 (12) ◽

pp. 1709-1718 ◽

Cited By ~ 1

Author(s):

K. Kalinsky ◽

J.R. Diamond ◽

L.T. Vahdat ◽

S.M. Tolaney ◽

D. Juric ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Previously Treated ◽

Basket Trial

A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

Surgery Today ◽

10.1007/s00595-013-0765-4 ◽

2013 ◽

Vol 44 (9) ◽

pp. 1678-1684 ◽

Cited By ~ 4

Author(s):

Kimihiro Tanaka ◽

Eriko Tokunaga ◽

Nami Yamashita ◽

Kenji Taketani ◽

Sayuri Akiyoshi ◽

...

Keyword(s):

Breast Cancer ◽

Luteinizing Hormone ◽

Aromatase Inhibitor ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Second Line ◽

Luteinizing Hormone Releasing Hormone ◽

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-1977-9 ◽

2012 ◽

Vol 71 (1) ◽

pp. 63-72 ◽

Cited By ~ 27

Author(s):

Francisco J. Esteva ◽

Stacy L. Moulder ◽

Ana M. Gonzalez-Angulo ◽

Joe Ensor ◽

James L. Murray ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Phase I Trial ◽

Metastatic Breast ◽

Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy

10.1158/0008-5472.sabcs13-s3-07 ◽

2013 ◽

Cited By ~ 6

Author(s):

D Paul ◽

SJ Vukelja ◽

FA Holmes ◽

J Blum ◽

KJ McIntyre ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Metastatic Breast ◽

Progression Free Survival ◽

First Line ◽

Free Survival ◽

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2021.05.035 ◽

2021 ◽

Vol 154 ◽

pp. 11-20

Author(s):

Yuan Yuan ◽

Jin Sun Lee ◽

Susan E. Yost ◽

Paul H. Frankel ◽

Christopher Ruel ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Hormone Receptor ◽

Metastatic Breast ◽